Yung-Chieh Chang

Employment

• Chang Gung University Asistant Research Fellow
  2026 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (18)

• Discovery of a novel miconazole analogue as a dual apo-IDO1 inhibitor and ABCB1 modulator for cancer immunotherapy and chemosensitizing
  European Journal of Pharmaceutical Sciences 2026 DOI: 10.1016/j.ejps.2026.107605
  +Save
• Tumor-derived RPS19 engages C5AR1+ inflammatory macrophages to drive astrocyte reprogramming and glioblastoma progression
  Cell Communication and Signaling 2026 DOI: 10.1186/s12964-026-03129-y
  +Save
• Synergistic Enhancement of PD-L1 Expression from DNA Repair Dysfunction and UV Exposure in Xeroderma Pigmentosum: Potential Therapeutic Role of PD-L1 Inhibitors.
  Journal of Dermatological Science 2026 DOI: 10.1016/j.jdermsci.2026.04.008
  +Save
• BIRC5 Promoter-Driven Nanodrugs Suppress BIRC5-Positive Cancers Independent of ABCB1 Status and IDO1 Expression
  International Journal of Nanomedicine 2026 DOI: 10.2147/IJN.S588571
  +Save
• EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis
  Neoplasia (United States) 2025 DOI: 10.1016/j.neo.2025.101193
  +Save
• Unraveling Cathepsin S Regulation in Interleukin-7-mediated Anti-tumor Immunity Reveals its Targeting Potential Against Oral Cancer.
  Journal of Biomedical Science 2025 DOI: 10.1186/s12929-025-01154-6
  +Save
• Did we miss something important? Rethinking the effects of autophagy and mitophagy on DNA damage repair and genomic stability.
  Journal of Cancer Metastasis and Treatment 2025 DOI: 10.20517/2394-4722.2025.33
  +Save
• NUPR1 contributes to endocrine therapy resistance by modulating BIRC5 expression and inducing luminal B-ERBB2 + subtype-like characteristics in estrogen receptor-positive breast cancer cells.
  Journal of Cancer 2025
  +Save
• NUPR1 contributes to endocrine therapy resistance by modulating BIRC5 expression and inducing luminal B-ERBB2+ subtype-like characteristics in estrogen receptor-positive breast cancer cells
  Journal of Cancer 2025 DOI: 10.7150/jca.105425
  +Save
• Development of a cancer cells self-activating and miR-125a-5p expressing poly-pharmacological nanodrug for cancer treatment
  International Journal of Molecular Medicine 2022 DOI: 10.3892/IJMM.2022.5158
  +Save
• YM155 and BIRC5 downregulation induce genomic instability via autophagy-mediated ROS production and inhibition in DNA repair
  Pharmacological Research 2021 DOI: 10.1016/j.phrs.2021.105474
  +Save
• An Updated Review of Smac Mimetics, LCL161, Birinapant, and GDC-0152 in Cancer Treatment
  Applied Sciences 2020 DOI: 10.3390/app11010335
  +Save
• BIRC5/Survivin is a novel ATG12–ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells
  Tzu‐Yu Lin, Hsiu-Han Chan, Shang‐Hung Chen +8 more
  Autophagy 2020 DOI: 10.1080/15548627.2019.1671643
  +Save
• Anti-apoptotic proteins in the autophagic world
  Journal of Biomedical Science 2020 DOI: 10.1186/s12929-020-0627-5
  +Save
• Mutation of the PTCH1 gene predicts recurrence of breast cancer
  Scientific Reports 2019 DOI: 10.1038/s41598-019-52617-4
  +Save
• HDAC2 and HDAC5 up-regulations modulate survivin and miR-125a-5p expressions and promote hormone therapy resistance in estrogen receptor positive breast cancer cells
  Frontiers in Pharmacology 2017 DOI: 10.3389/fphar.2017.00902
  +Save
• YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells
  Siao Muk Cheng, Yung-Chieh Chang, C Y Liu +12 more
  British Journal of Pharmacology 2015 DOI: 10.1111/bph.12935
  +Save
• Survivin - biology and potential as a therapeutic target in oncology
  OncoTargets and Therapy 2013 DOI: 10.2147/OTT.S33374
  +Save